Delivery Order SPE2DB22D9239-SPE2DB24FDK68

Award Date 6/27/24
Potential Completion Date 7/19/24
Potential Value $109K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 firm fixed-price delivery order is for the supply of XENPOZYME 20 MG VIALS, with a period of performance through October 29, 2024. This award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $109,272.60 firm fixed-price delivery order contract is for the supply of XENPOZYME 20 MG VIALS, which are likely a specialized pharmaceutical product. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 firm fixed-price contract is for the supply of XENPOZYME 20 MG VIALS, a pharmaceutical product. The award falls under a larger indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA, valued at up to $499,999,999, to provide a comprehensive range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $87,418.08, is for the delivery of Xenpozyme 20 mg vials, a pharmaceutical product. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 9, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply...
This is a $87,418.08 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award covers the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through February 10, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 firm fixed-price delivery order is for the supply of Xenpozyme 20 mg vials, a specialized pharmaceutical product, with a period of performance through December 31, 2024. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The contract has a ceiling value of $72,848.30 and is a firm fixed-price delivery order for the pharmaceutical product XENPOZYME 20 MG VIALS. The contract has an ultimate completion date of September 14, 2023. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The contract, valued at $109,272.60, is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product. The order has an ultimate completion date of March 29, 2024 and is not set aside for any specific business category. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract,...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDK68
    Delivery Order

The federal contract award is to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $109,272.60, is a delivery order awarded by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a completion date of July 19, 2024. The contract has a firm fixed price pricing type and does not have a set-aside designation. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide.

Generated 9/26/24, 9:16 AM